Antiretroviral Drugs Market to expand with over 4% CAGR through 2024

November 06, 2019


According to the latest study titled ‘Global Antiretroviral Drugs Market: Analysis By Drug Type (Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors), By Region, By Country, Drug Forecast (2019 Edition): Opportunities and Forecast (2013-2023) - By Region (North America, Europe, APAC, ROW), By Country (U.S., Canada, Germany, U.K, France, Italy, China, Japan, India, South Africa)’ available at MarketStudyReport.com, the global antiretroviral drugs market is estimated to grow with a CAGR of 4.70% through 2024.
 

Antiretroviral drugs are used to treat severe infections caused by retroviruses. Increasing prevalence of AIDS worldwide along with the availability of new drugs with better efficacy and rising antiretroviral treatment coverage rate are the factors driving the growth of antiretroviral drugs industry share.
 

Not to mention, the rise in medical expenditure and the presence of a stringent regulatory spectrum pertaining to HIV in various countries will also augment the industry trends. Furthermore, reduced cost of treatment, improved diagnosis rate, and rise in the favorable programs to provide diagnosis and treatment facilities to the unmet patient population will also drive the growth of antiretroviral drugs market.
 

The study encompasses details about segmental shares, and expansion strategies adopted by manufacturers, alongside the challenges, drivers influencing the industry growth, trends, as well as restraints impacting the market growth.
 

Based on drug type, the antiretroviral drugs market is segmented into nucleoside reverse transcriptase inhibitors (NRTI), multi-class drugs combination, non-nucleoside reverse transcriptase inhibitors (NNRTI), protease inhibitors, and others.
 

Speaking of NRTI, the industry is divided into Epzicom, and Kivexa. While based on multi-class drugs combination, the antiretroviral drugs market is split into Genvoya, Triumeq, Stribild, Odefsey, and Biktarvy. Considering the protease inhibitors, the industry is bifurcated into Prezista, Prezcobix, and Rezolsta. Whereas based on the non-nucleoside reverse transcriptase inhibitors type, the industry is divided into Edurant.
 

Request sample copy of this Report@ https://www.marketstudyreport.com/request-a-sample/1856955/
 

As per the report, in terms of integrase strand transfer inhibitors, the antiretroviral drugs market is segmented into Tivicay, Isentress, and Isentress HD. While based on CCR5 Inhibitor, the industry is divided into Selzentry and Celsentri.
 

While considering the geographical landscape, the antiretroviral drugs market is divided into four major regions, namely, North America, Europe, APAC, and the rest of the world.
 

The key players of antiretroviral drugs market are ViiV Healthcare, Gilead Sciences Inc., AbbVie Inc., Bristol-Myers Squibb, Johnson & Johnson, Boehringer Ingelheim, Cipla, Mylan, and Merck & Co.


Frequently Asked Questions (FAQ) :

Increasing prevalence of AIDS, availability of new drugs with better efficacy and increasing antiretroviral treatment coverage rate are the factors driving the growth of antiretroviral drugs. Not to mention, the rise in medical expenditure, the presence of a stringent regulatory spectrum pertaining to HIV in various countries, reduced cost of treatment, improved diagnosis rate, and rise in the favorable programs to provide diagnosis and treatment facilities to the unmet patient population will also drive the growth of antiretroviral drugs market.
The global antiretroviral drugs market is estimated to grow with a CAGR of 4.70% through 2024.
Based on drug type, the antiretroviral drugs market is segmented into nucleoside reverse transcriptase inhibitors (NRTI), multi-class drugs combination, non-nucleoside reverse transcriptase inhibitors (NNRTI), protease inhibitors, and others.
Companies that a part of the copetitive spectrum of antiretroviral drugs market are ViiV Healthcare, Gilead Sciences Inc., AbbVie Inc., Bristol-Myers Squibb, Johnson & Johnson, Boehringer Ingelheim, Cipla, Mylan, and Merck & Co.